OTC Markets OTCPK - Delayed Quote USD

Otsuka Holdings Co., Ltd. (OTSKY)

23.64

-0.03

(-0.13%)

At close: April 25 at 4:00:00 PM EDT

EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

Pharmaceutical Technology last month

OTSKY
-0.13%
Otsuka’s sibeprenlimab shows promise in Phase III IgA nephropathy trial

Interim data from Otsuka's trial of sibeprenlimab indicates a significant reduction in proteinuria in IgA nephropathy patients.

Clinical Trials Arena 5 months ago

OTSKY
-0.13%
Otsuka’s startup bet pays off with kidney disease drug results

A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

BioPharma Dive 5 months ago

OTSKY
-0.13%
Otsuka snaps up Jnana with its phenylketonuria drug for $800m

The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s Phase I/II phenylketonuria therapy to its rare disease portfolio.

Clinical Trials Arena 8 months ago

OTSKY
-0.13%
SYBX
Otsuka buys startup Jnana, adding to uptick in private biotech M&A

The $800 million deal hands Otsuka a drug that’s shown promise in early testing in phenylketonuria, and is the fourth buyout of a privately held biotech in the last two weeks alone.

BioPharma Dive 8 months ago

OTSKY
-0.13%
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

Zacks 10 months ago

IONS

OTSKY
-0.13%
NVS
Otsuka and Lundbeck report data from three PTSD treatment trials

In the trials, the brexpiprazole plus sertraline regimen was associated with a statistically significant reduction in PTSD symptoms.

Clinical Trials Arena 10 months ago

OTSKY
-0.13%

Performance Overview

Return	OTSKY	Nikkei 225 (^N225)
YTD	-13.25%	-10.50%
1-Year	+16.00%	-5.11%
3-Year	+44.76%	+34.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Otsuka Holdings Co., Ltd. (OTSKY)

EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia

Otsuka’s sibeprenlimab shows promise in Phase III IgA nephropathy trial

Otsuka’s startup bet pays off with kidney disease drug results

Otsuka snaps up Jnana with its phenylketonuria drug for $800m

Otsuka buys startup Jnana, adding to uptick in private biotech M&A

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

Otsuka and Lundbeck report data from three PTSD treatment trials

Performance Overview